title: Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
authors: III. Department of Medicine, Technical University of Munich, Munich.
authors: Catharina
authors: C
authors: Müller-Thomas
authors: Institute of Pathology, Julius-Maximilians-University Würzburg, Munich.
authors: Martina
authors: M
authors: Rudelius
authors: Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich.
authors: Ina-Christine
authors: IC
authors: Rondak
authors: MLL, Munich Leukemia Laboratory, Munich.
authors: Torsten
authors: T
authors: Haferlach
authors: Department of Hematology and Oncology, Georg-August-University Göttingen, Munich.
authors: Julie
authors: J
authors: Schanz
authors: III. Department of Medicine, Technical University of Munich, Munich.
authors: Christina
authors: C
authors: Huberle
authors: Hematology and Oncology Pasing, Munich.
authors: Burkhard
authors: B
authors: Schmidt
authors: Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich.
authors: Rainer
authors: R
authors: Blaser
authors: Institute of Pathology Harlaching, Munich.
authors: Marcus
authors: M
authors: Kremer
authors: III. Department of Medicine, Technical University of Munich, Munich German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg.
authors: Christian
authors: C
authors: Peschel
authors: Department of Hematology and Oncology, Heinrich-Heine-University Düsseldorfand.
authors: Ulrich
authors: U
authors: Germing
authors: German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg I. Department of Medicine, Gustav-Carus-University Dresden, Dresden, Germany.
authors: Uwe
authors: U
authors: Platzbecker
authors: III. Department of Medicine, Technical University of Munich, Munich German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg k.goetze@lrz.tum.de.
authors: Katharina
authors: K
authors: Götze
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D015870:Gene Expression; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics* / Q000401:mortality; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; D016159:Tumor Suppressor Protein p53; D001374:Azacitidine
keywords: MDS; TP53 mutations; azacitidine; p53 expression